Explore LL-37 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
LL-37 is the only known human cathelicidin antimicrobial peptide, produced by neutrophils and epithelial cells as part of the innate immune response. It is studied for its roles in immune modulation, wound healing, angiogenesis, and defense against bacterial biofilms. This data reveals the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their LL-37 reconstitution protocol.
LL-37 is the only known human cathelicidin antimicrobial peptide — a 37-amino-acid amphipathic α-helical peptide cleaved from the C-terminus of the precursor protein hCAP-18, encoded by the CAMP gene and stored in the secondary granules of neutrophils, with additional expression in keratinocytes, epithelial cells of the airway and gut, and mast cells.
LL-37 is a 37-residue human cathelicidin peptide — the body's only cathelicidin — most often sourced for antimicrobial, wound-healing, and immune research. It works as both a broad-spectrum antimicrobial and an immune-signaling molecule. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
LL-37 is amphipathic and α-helical; it inserts into negatively charged bacterial membranes (which expose anionic phospholipids and lipopolysaccharide that mammalian membranes do not) and disrupts membrane integrity, killing a wide range of Gram-positive, Gram-negative, fungal, and enveloped-viral pathogens. Beyond direct microbial killing, LL-37 binds the formyl-peptide receptor 2 (FPR2/ALX) on neutrophils, monocytes, and endothelial cells to drive chemotaxis, modulate cytokine release, and accelerate wound healing — the basis for its established role in cutaneous host defence and wound repair.
Topical and parenteral LL-37 has been investigated in chronic wound healing, venous leg ulcers (Gronberg et al., Phase 2 randomised trial reported accelerated healing), inflammatory skin conditions, and adjunct antimicrobial therapy for antibiotic-resistant infections. LL-37 has also been studied as a biomarker in vitamin-D-dependent host defence and in the pathophysiology of psoriasis and rosacea where it can drive autoinflammation. No FDA-approved LL-37 drug product exists, though it is in active early-stage clinical development.
LL-37 has a reported half-life of ~30–60 min, and the dose intervals researchers model most often fall around once daily. Short half-life — this cathelicidin peptide clears within about an hour, so daily dosing acts per-dose with no meaningful systemic accumulation. It is catalogued under Skin Peptides on WPA.
43 LL-37 reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (13 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 5mg (34 sessions). The most common dosing frequency is once weekly (2 logged protocols), followed by 2x/week (2).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.